Review article · 2023 · Open access

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy

Yujeong Moon, Seong Ik Jeon, Man Kyu Shim, Kwangmeyung Kim

Pharmaceutics, 15(2), 411 · Published 26 January 2023 · DOI 10.3390/pharmaceutics15020411

Open PDFView at the publisherCite this paper

In brief

“Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy” is a 2023 review article by Yujeong Moon and 3 co-authors, published in Pharmaceutics. OpenAlex counts 60 citations as of 21 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Pharmaceutics.

Citations
60
Most cited in
2025 (20)
Field-weighted impact
1.37
References
162
Authors
4

Abstract

Proteolysis-targeting chimeras (PROTACs) are rapidly emerging as a potential therapeutic strategy for cancer therapy by inducing the degradation of tumor-overexpressing oncogenic proteins. They can specifically catalyze the degradation of target oncogenic proteins by recruiting E3 ligases and utilizing the ubiquitin-proteasome pathway. Since their mode of action is universal, irreversible, recyclable, long-lasting, and applicable to 'undruggable' proteins, PROTACs are gradually replacing the role of conventional small molecular inhibitors. Moreover, their application areas are being expanded to cancer immunotherapy as various types of oncogenic proteins that are involved in immunosuppressive tumor microenvironments. However, poor water solubility and low cell permeability considerably restrict the pharmacokinetic (PK) property, which necessitates the use of appropriate delivery systems for cancer immunotherapy. In this review, the general characteristics, developmental status, and PK of PROTACs are first briefly covered. Next, recent studies on the application of various types of passive or active targeting delivery systems for PROTACs are introduced, and their effects on the PK and tumor-targeting ability of PROTACs are described. Finally, recent drug delivery systems of PROTACs for cancer immunotherapy are summarized. The adoption of an adequate delivery system for PROTAC is expected to accelerate the clinical translation of PROTACs, as well as improve its efficacy for cancer therapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Moon, Y., Jeon, S. I., Shim, M. K., & Kim, K. (2023). Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. Pharmaceutics, 15(2), 411. https://doi.org/10.3390/pharmaceutics15020411

MLA 9

Moon, Yujeong, et al. “Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy.” Pharmaceutics, vol. 15, no. 2, 2023, p. 411. https://doi.org/10.3390/pharmaceutics15020411.

Chicago

Moon, Yujeong, Seong Ik Jeon, Man Kyu Shim, and Kwangmeyung Kim. 2023. “Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy.” Pharmaceutics 15 (2): 411. https://doi.org/10.3390/pharmaceutics15020411.

Harvard

Moon, Y. et al. (2023) ‘Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy’, Pharmaceutics, 15(2), p. 411. doi:10.3390/pharmaceutics15020411.

IEEE

Y. Moon, S. I. Jeon, M. K. Shim, and K. Kim, “Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy,” Pharmaceutics, vol. 15, no. 2, p. 411, 2023, doi: 10.3390/pharmaceutics15020411.

BibTeX

@article{moon2023cancer,
  title     = {{Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy}},
  author    = {Moon, Yujeong and Jeon, Seong Ik and Shim, Man Kyu and Kim, Kwangmeyung},
  journal   = {Pharmaceutics},
  year      = {2023},
  volume    = {15},
  number    = {2},
  pages     = {411},
  doi       = {10.3390/pharmaceutics15020411},
  url       = {https://doi.org/10.3390/pharmaceutics15020411}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202377
20241616
20252020
20261717

Its field-weighted citation impact is 1.37: it has been cited 1.37 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • cancer immunotherapy
  • drug delivery systems
  • E3 ubiquitin ligase
  • ubiquitin-proteasome system
  • immunosuppressive tumor microenvironment
  • pharmacokinetics
  • tumor targeting

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Moon, Y., Jeon, S. I., Shim, M. K., & Kim, K. (2023). Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. Pharmaceutics, 15(2), 411. https://doi.org/10.3390/pharmaceutics15020411

How many times has this paper been cited?

60 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Pharmaceutics: sign in and open the PDF from this page.

Who wrote this paper?

Yujeong Moon, Seong Ik Jeon, Man Kyu Shim, Kwangmeyung Kim.

What is the DOI of this paper?

10.3390/pharmaceutics15020411, permanently at https://doi.org/10.3390/pharmaceutics15020411. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.